Itpr1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Inositol 1,4,5-Trisphosphate Receptor Type 1 |
|---|
| Gene Symbol | ITPR1 |
| Full Name | Inositol 1,4,5-Trisphosphate Receptor Type 1 |
| Chromosomal Location | 3p26.1 |
| NCBI Gene ID | 3708 |
| Ensembl ID | ENSG00000151952 |
| UniProt ID | Q14643 |
| Associated Diseases | Spinocerebellar Ataxia Type 15, Alzheimer's Disease, Huntington's Disease, SCA29, Autism |
ITPR1 is a gene that encodes a protein involved in inositol trisphosphate receptor and calcium signaling. This gene is implicated in neurodegenerative diseases and represents a potential therapeutic target.
ITPR1 encodes the inositol 1,4,5-trisphosphate receptor type 1 (IP3R1), a ligand-gated calcium release channel located on the endoplasmic reticulum (ER) membrane. IP3R1 mediates calcium signaling in response to various stimuli by releasing Ca²⁺ from intracellular stores into the cytoplasm. This receptor is particularly crucial in neurons where it regulates synaptic plasticity, gene expression, and cellular excitability[1]. Mutations in ITPR1 cause spinocerebellar ataxia type 15 (SCA15), making it one of the few genes directly linked to both cerebellar degeneration and neurodegenerative diseases[2].
- Chromosomal location: 3p26.1
- Genomic size: ~270 kb
- Exons: 58 exons
- Alternative splicing: Multiple splice variants
- Length: ~2,700 amino acids per monomer
- Molecular weight: ~300 kDa per subunit
- Quaternary structure: Tetrameric assembly
¶ Domain Organization
| Domain |
Function |
| N-terminal (IP3-binding) |
Binds IP3, regulatory domains |
| Suppressor domain |
Modulates channel activity |
| Linker region |
Couples ligand binding to gate |
| Channel domain |
Forms Ca²⁺ pore (6 TMs) |
| C-terminal (gate) |
Regulatory and tetramerization |
- IP3-binding domain: N-terminal ~600 aa
- Calcium-binding sites: Multiple regulatory sites
- Phosphorylation sites: PKA, CaMKII, PKG
- Receptor activation generates IP3
- IP3 binds to N-terminal domain
- Conformational change opens channel
- Ca²⁺ flows from ER to cytoplasm
- Calcium: Biphasic regulation (activates at low, inhibits at high)
- IP3 concentration: Cooperative activation
- Phosphorylation: Modulates sensitivity
- Protein interactions: Multiple regulatory bindings
- Ryanodine receptors: Cross-talk with Ca²⁺ release
- Store-operated channels: Capacitative calcium entry
- Mitochondrial calcium: Calcium uptake regulation
- ER chaperones: Quality control
- Highest in cerebellum (Purkinje cells)
- Substantial expression in hippocampus
- Present in cortex, basal ganglia
- Endoplasmic reticulum membrane
- Postsynaptic densities
- Dendritic shafts and spines
- Inheritance: Autosomal dominant
- Mechanism: Heterozygous deletions or missense mutations
- Phenotype: Progressive ataxia, cerebellar atrophy
- Pathology: Purkinje cell degeneration
- Calcium dysregulation: Core feature of AD neurons
- IP3R1 alterations: Changed expression and function
- Aβ effects: Impairs IP3-mediated signaling
- Therapeutic target: Restoration of calcium homeostasis
- Transcriptional dysregulation: Altered ITPR1 expression
- Calcium signaling: Mutant HTT affects IP3R1 function
- Excitotoxicity: Enhanced vulnerability
- Rare variants: De novo mutations identified
- Synaptic function: Altered calcium signaling
- IP3R modulators: Channel agonists/antagonists
- Calcium stabilizers: Restore neuronal calcium homeostasis
- Neuroprotective strategies: Target excitotoxicity
- Calcium imaging: IP3R as biomarker
- Gene therapy: Viral vector approaches
- Structure-function: High-resolution structures
- Therapeutic targeting: Selective modulators
- Genetics: Variant pathogenicity
- Biomarkers: Calcium signaling dysfunction
- Animal models: Knockout and transgenic
- ITPR1 knockout: Cerebellar dysfunction
- Conditional knockouts: Tissue-specific deletion
- Disease models: SCA15 knock-in
The study of Itpr1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Berridge MJ. Inositol trisphosphate and calcium signalling. Nature. 1993;361(6410):315-325.
[2] van de Leemput J, et al. Deletion at ITPR1 underlies ataxia in mice and humans. Brain. 2007;130(Pt 8):2174-2182.